Acute administration of alprazolam, alcohol and their combination on cognitive performance and mood: A randomised, double-blind, placebo-controlled study.

التفاصيل البيبلوغرافية
العنوان:	Acute administration of alprazolam, alcohol and their combination on cognitive performance and mood: A randomised, double-blind, placebo-controlled study.
المؤلفون:	Aitken B; Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia., Hayley AC; Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.; Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia., Ford TC; Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.; Cognitive Neuroscience Unit, Deakin University, Geelong, VIC, Australia., Geier L; Forensic Science SA, Adelaide, SA, Australia., Shiferaw BA; Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.; Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia.; Seeing Machines Ltd., Fyshwick, ACT, Australia., Downey LA; Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.; Institute for Breathing and Sleep, Austin Health, Heidelberg, VIC, Australia.
المصدر:	Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2023 Dec; Vol. 37 (12), pp. 1227-1237. Date of Electronic Publication: 2023 Sep 19.
نوع المنشور:	Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: Sage Publications Country of Publication: United States NLM ID: 8907828 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1461-7285 (Electronic) Linking ISSN: 02698811 NLM ISO Abbreviation: J Psychopharmacol Subsets: MEDLINE
أسماء مطبوعة:	Publication: Thousand Oaks, CA : Sage Publications Original Publication: Oxford, UK : Oxford University Press,
مواضيع طبية MeSH:	Alprazolam/pharmacology , Blood Alcohol Content, Humans ; Female ; Adult ; Male ; Hypnotics and Sedatives/adverse effects ; Ethanol/adverse effects ; Cognition ; Double-Blind Method
مستخلص:	Background: Recreational co-consumption of benzodiazepines and alcohol is a common practise; yet, the cognitive effects of this combination remain poorly understood. This study aimed to investigate the acute cognitive effects of combining a 1 mg dose of alprazolam with a moderate dose of alcohol (target 0.04% blood alcohol concentration (BAC)) in a non-clinical population. Methods: In this randomised, double-blind, placebo-controlled, crossover trial, participants completed computerised cognitive assessments and the brief biphasic alcohol effects scale (B-BAES) after consuming 1 mg of alprazolam, both with and without a moderate dose of alcohol (target 0.04% BAC). Results: Among 20 healthy participants (mean age = 28.6, SD ± 4.0 years, 60% female), we found that a peak BAC of 0.03% had no significant impact on cognitive performance. Both the individual use of alprazolam and its combination with alcohol resulted in impaired reaction time, digit vigilance, and verbal, spatial and numeric working memory tasks, although an additive effect when alcohol and alprazolam were consumed together was not evident. The most pronounced cognitive effects occurred at 100 min after dosing, coinciding with increased alprazolam concentrations. Sedative effects were heightened with alcohol, alprazolam and their combination while no stimulative effects were reported. Conclusions: Our findings highlight the significant implications of a therapeutic dose of alprazolam on impairing cognitive performance. This is particularly relevant considering the frequency of non-medical alprazolam use. Future studies should explore different dosages, administration timings and long-term effects to inform the development of public health policies and guidelines regarding the combined use of alcohol and benzodiazepines. Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Amie C Hayley is currently supported by a Rebecca L Cooper Al and Val Rosenstrauss Fellowship (GNT: F2021894) and was previously supported by an NHMRC Early Career Fellowship (GNT: 1119960) during the conduct of this study. Luke A Downey was supported by a R.D. Wright Biomedical Career Development Fellowship (GNT: 1122577) during the conduct of this study. Blair Aitken, Talitha Ford, Lauren Geier, and Brook A Shiferaw have no conflicts of interests to declare.
References:	J Stud Alcohol Drugs. 2021 Sep;82(5):553-563. (PMID: 34546901) Addict Biol. 2007 Jun;12(2):183-9. (PMID: 17508991) Alcohol Clin Exp Res. 1999 May;23(5):815-21. (PMID: 10371400) Clin Pharmacol Ther. 1982 Aug;32(2):201-7. (PMID: 6124334) Eur J Clin Pharmacol. 1992;42(4):439-43. (PMID: 1516609) Natl Health Stat Report. 2020 Jan;(137):1-16. (PMID: 32510318) Eur J Clin Pharmacol. 1992;42(5):495-8. (PMID: 1606995) Hum Psychopharmacol. 2017 Nov;32(6):. (PMID: 28983971) Hum Psychopharmacol. 2014 Jul;29(4):370-83. (PMID: 24930981) Psychopharmacology (Berl). 1993;110(4):471-8. (PMID: 7870919) Eur J Clin Pharmacol. 1990;39(1):21-8. (PMID: 2276384) Hum Psychopharmacol. 2014 Jul;29(4):360-9. (PMID: 25163441) J Psychopharmacol. 2019 Jul;33(7):791-800. (PMID: 30912701) Psychopharmacologia. 1974 Jun 21;37(4):159-68. (PMID: 4844120) PLoS One. 2019 Jan 9;14(1):e0209239. (PMID: 30625179) Psychopharmacology (Berl). 2022 Dec;239(12):3893-3902. (PMID: 36322184) Eur J Clin Pharmacol. 1992;43(6):603-11. (PMID: 1493841) Drug Saf. 2011 Feb 1;34(2):125-56. (PMID: 21247221) Alcohol Clin Exp Res. 2013 Mar;37(3):470-6. (PMID: 23078583) Eur J Clin Pharmacol. 1991;40(4):355-62. (PMID: 2050170) Am J Public Health. 2016 Apr;106(4):686-8. (PMID: 26890165) Psychopharmacology (Berl). 1995 Mar;118(1):1-9. (PMID: 7597114) Accid Anal Prev. 2021 May;154:106052. (PMID: 33676142) Exp Clin Psychopharmacol. 1997 Feb;5(1):28-38. (PMID: 9234037) Hum Psychopharmacol. 2019 Nov;34(6):e2715. (PMID: 31837049) Accid Anal Prev. 2015 Jan;74:210-7. (PMID: 25463962) Psychopharmacology (Berl). 1995 Oct;121(4):442-50. (PMID: 8619007) Eur J Clin Pharmacol. 1982;23(6):509-12. (PMID: 7160419) Sleep Med. 2001 Jul;2(4):323-332. (PMID: 11438249) J Stud Alcohol Drugs. 2015 Nov;76(6):952-6. (PMID: 26562604) Neurosci Biobehav Rev. 2021 Jul;126:175-193. (PMID: 33497784) Clin Toxicol (Phila). 2017 Jul;55(6):545-556. (PMID: 28277803) Psychopharmacology (Berl). 2007 May;191(4):951-9. (PMID: 17219217) Psychopharmacology (Berl). 2021 Jul;238(7):1965-1977. (PMID: 33813611) Ann Pharmacother. 2013 Feb;47(2):257-68. (PMID: 23362039) Int J Geriatr Psychiatry. 2017 Dec;32(12):e83-e92. (PMID: 28128869) Acta Pharmacol Toxicol (Copenh). 1974 Jan;34(1):5-15. (PMID: 4597697) Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911. (PMID: 29244060) Drug Alcohol Depend. 2019 Jul 1;200:95-114. (PMID: 31121495) Int J Neuropsychopharmacol. 2021 Jul 23;24(7):551-561. (PMID: 33667308) Br J Clin Pharmacol. 1979;7 Suppl 1:91S-97S. (PMID: 35214)
فهرسة مساهمة:	Keywords: Alprazolam; alcohol; benzodiazepines; cognitive performance; randomised controlled trial
المشرفين على المادة:	YU55MQ3IZY (Alprazolam) 0 (Blood Alcohol Content) 0 (Hypnotics and Sedatives) 3K9958V90M (Ethanol)
تواريخ الأحداث:	Date Created: 20230919 Date Completed: 20231216 Latest Revision: 20240430
رمز التحديث:	20240430
مُعرف محوري في PubMed:	PMC10714690
DOI:	10.1177/02698811231200878
PMID:	37724443
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	1461-7285
DOI:	10.1177/02698811231200878